Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch
  

Nycomed Gmbh patents

Recent patent applications related to Nycomed Gmbh. Nycomed Gmbh is listed as an Agent/Assignee. Note: Nycomed Gmbh may have other listings under different names/spellings. We're not affiliated with Nycomed Gmbh, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "N" | Nycomed Gmbh-related inventors




Date Nycomed Gmbh patents (updated weekly) - BOOKMARK this page
09/05/13Novel process for the preparation of roflumilast
08/29/13Novel process for the preparation of roflumilast
06/06/13Use of ciclesonide for the treatment of respiratory diseases
05/23/13Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
04/18/13Ciclesonide containing aqueous pharmaceutical composition
04/18/13Novel salts of 6-heterocycle substituted hexahydrophenanthridine derivatives
02/21/13Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors
01/10/13Pyrazolone derivatives as pde4 inhibitors
11/22/12Novel process for the preparation of roflumilast
11/15/123,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c] isoquinoline derivatives
10/04/12Stabilized pharmaceutical product
08/02/12Composition comprising a pde4 inhibitor and a pde5 inhibitor
06/14/12Methylpyrrolopyrimidinecarboxamides
06/07/12Methylpyrrolopyridinecarboxamides
05/24/12Combination treatment for diabetes mellitus
04/19/12The aerosolization of large volumes of dry powder
04/05/12Pharmaceutical product for injection
03/01/12Treatment of chronic obstructive pulmonary disease with phosphodiesterase-4 inhibitor
12/22/11Stabilized pharmaceutical product
12/22/11Container having a tearable packet therein
12/22/11Topically applicable pharmaceutical preparation
11/03/11Roflumilast for the treatment of diabetes mellitus
10/20/11Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors
10/20/11Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors
10/13/11Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
09/08/11Novel pyrazolone-derivatives and their use as pde-4 inhibitors
07/14/11Dosage form containing (s)-pantoprazole as active ingredient
06/09/11Triazolophthalazines
05/12/11Filtering device, filtering of a fluid, and use of the filtering device
04/21/11Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
04/14/11Combination medicament
03/17/11Stable pharmaceutical products
03/10/11Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
02/24/11Tetrahydrobenzothiophene derivatives
01/27/11Pyrrolopyrimidinecarboxamides
12/16/10Imidazopyridine derivatives useful as inos inhibitors
11/11/10Triazolophthalazines
09/30/10Stabilized pharmaceutical product
09/16/10Composition comprising a pde4 inhibitor and a pde5 inhibitor
07/29/10Novel salts of 6-heterocycle substituted hexahydrophenanthridine derivatives
07/15/10Combination treatment for diabetes mellitus
07/15/10Novel use for pde5 inhibitors
05/13/106-benzyl-2,3,4,7-tetrahydro-indolo [2,3-c] quinoline compounds useful as pde5 inhibitors
05/13/10Pyrazolone derivatives as pde4 inhibitors
03/18/10Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary disease
02/11/10Ciclesonide-containing sterile aqueous suspension
02/11/10Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiestrase (pde) 4 inhibitors
01/28/10Isotopically substituted proton pump inhibitors
12/03/09Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
10/29/09Novel tetrahydropyridothiophenes
10/22/09Novel sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles
09/24/09Novel 3-thia-10-aza-phenanthrene derivatives
08/27/09Device for dosing and dry nebulization
08/27/09Roflumilast for the treatment of pulmonary hypertension
08/20/09Dosage form containing pantoprazole as active ingredient
08/20/09Pharmaceutical product for injection
07/02/09Cellular assay identifying pkc-0 inhibitors
07/02/093-hydroxy-6-phenylphenanthridines as pde4 inhibitors
07/02/09Novel process for the preparation of roflumilast
05/28/09Method
05/21/09Imidazopyridine derivatives useful as inos inhibitors
05/21/092-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
05/07/09Sulfonylpyrroles as histone deacetylase inhibitors
04/09/09Freeze-dried pantoprazole preparation and pantoprazole injection







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Nycomed Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Nycomed Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';